Novo Nordisk Confronts Its Promised Second-Half Slowdown As Wegovy Pill Carries The Load

Novo Nordisk heads into its third-quarter report with a strange disconnect. Management has raised its full-year outlook three times in a row and returned the business to growth last quarter, yet the stock has fallen almost 18% since that report while the S&P 500 barely moved. The November 4 release, due before the open, is the first real test of whether the company's improving commercial story can hold up through a stretch that management itself warned would look weaker on paper.

The Street is braced for contraction. Consensus calls for earnings of $0.81 per share, down about 21% from $1.02 a year ago, on revenue of $11.39 billion, roughly 3% below the year-ago quarter and a clear step down from the $12.21 billion posted last quarter. That decline is largely by design. Management signaled that the second half would shrink by around 5% because roughly DKK 5 billion of favorable gross-to-net adjustments in the back half of 2025 will not repeat, and because semaglutide's loss of exclusivity in Canada and Brazil hits later in the year. Notably, the Earnings Whisper sits at $0.90, about 11% above consensus, suggesting the more informed bar is meaningfully higher than published estimates and that a merely in-line print may not satisfy.

Guidance frames the stakes. The latest outlook calls for 2026 revenue of $43.99 billion to $46.79 billion, up from $41.18 billion to $44.92 billion, and consensus of $44.57 billion sits in the lower half of that range. That leaves room for upside, but it also means analysts are not fully buying management's optimism. The guidance path matters too: the sales and operating profit range has moved from a decline of 5% to 13% initially, to 4% to 12%, and then to flat to down 6%. After three raises, another lift would signal genuine momentum, while a reiteration could read as confidence peaking.

The Wegovy pill is the engine to watch. Weekly US prescriptions climbed from 207,000 in April to 267,000 by mid-July, with the oral drug holding roughly 90% of the US oral obesity market despite a competitor's entry. Validation would mean continued US prescription growth plus visible contributions from the ex-US rollout, where the UK added about 300,000 patients in three weeks and Germany was slated to launch in September. The Medicare Part D Bridge program and the higher-dose 7.2mg pen in Europe should also start showing up. A challenge to the narrative would come if pill volume growth flattens or if US injectable price erosion, which drove a 22% decline last quarter, deepens under the most-favored-nation pricing agreement and Medicaid coverage cuts.

Margins are the second swing factor. Adjusted gross margin slid to 78.2% last quarter from 82.7% a year earlier, though about DKK 3 billion of that hit was a one-time manufacturing rightsizing charge. Without that charge, a rebound toward the 80% level would suggest the underlying erosion is manageable. A margin that stays depressed would point to pricing doing more damage than volume can offset. Transformation savings, which management described as running ahead of plan toward DKK 8 billion, should help cushion operating profit.

Sentiment has soured, with bearish readings rising to 56.2% from 45.5% heading into last quarter, likely reflecting the failed siltivecumab cardiovascular trial and Cagri-Sema's disappointing blood sugar showing against tirzepatide. At $39.13, the stock trades well below its 200-day average of $44.66 and closer to the bottom of its post-earnings range of $36.85 to $49.15. That pessimism lowers the bar somewhat, but the central question is simple: can oral Wegovy volume and cost discipline outrun pricing pressure and patent expirations well enough to keep full-year guidance moving up rather than stalling?

This earnings preview was originally published on Earnings Whispers.

This article is for informational purposes only and is not investment advice. Earnings Whispers and its staff may hold positions in the securities mentioned. It is AI-assisted, based on proprietary Earnings Whispers data and company reports, and edited by Earnings Whispers staff.